Meropenem trihydrate

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

119478-56-7

包装与价格：

包装	价格(元)
10mM (in 1mL H2O)	询价
25mg	询价
50mg	询价
100mg	询价
250mg	询价

化学性质

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	437.51
Cas No.	119478-56-7
Formula	C17H31N3O8S
Solubility	≥20.7 mg/mL in H2O with gentle warming; insoluble in EtOH; ≥49.2 mg/mL in DMSO
Chemical Name	(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;trihydrate
Canonical SMILES	CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O.O.O.O
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Meropenem trihydrate(SM-7338)是一种活性成分碳青霉烯类抗生素 [1].

Meropenem trihydrate有效抑制革兰氏阴性生物体,对大肠杆菌(30)\肺炎克雷伯菌(29)\产酸克雷伯菌(20)\产气肠杆菌(14)\阴沟肠杆菌(29)\弗氏柠檬酸杆菌(20)\异型枸橼酸杆菌(12)\奇异变形杆菌(15)和摩氏摩根氏菌(15)的MIC90值分别为0.03 μM\0.06 μM\0.06 μM\0.12 μM\0.25 μM\0.12 μM\0.06 μM\0.12 μM和0.25 μM.Meropenem trihydrate也抑制革兰氏阳性菌和厌氧菌,对化脓性链球菌(20)\草绿色链球菌(27)和肺炎链球菌(15)的MIC90值分别为0.008 μM\4 μM和0.015 μM.此外,不同pH可以影响Meropenem trihydrate的MIC值,例如,当pH值为5.5和7.5时,相应MIC平均值为0.06 μM和0.03 μM[1].

参考文献：
[1] Neu HC1, Novelli A, Chin NX. In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338.Antimicrob Agents Chemother. 1989 Jul; 33(7):1009-18.

试验操作

Animal experiment:[1]
Animal models	Male Sprague-Dawley rats (250 ~ 350 g) with acute necrotizing pancreatitis
Dosage form	60 mg/kg Once daily by intraperitoneal injection
Applications	Meropenem treatment significantly reduced hemorrhage and fat necrosis scores, as well as the incidence of pancreatic infection. When meropenem was combined with deferoxamine, improvements could be observed in all parameters including edema, acinar necrosis, inflammatory infiltrate, hemorrhage, fat necrosis, and perivascular inflammation. However, the difference between combined treatment and meropenem treatment did not reach to statistical significance.
Note	The technical data provided above is for reference only.
	References: 1. Ateskan U, Mas MR, Yasar M, et al. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas, 2003, 27(3): 247-252.